MRD-guided Chemo Timing for Early Colon Cancer
Part of Cancer, Digestive system clinical trials.
This trial is for people with early-stage colon cancer (stage II high-risk or stage III low-risk) that is not MSI-H. It uses a blood test (MRD) to see if you can safely delay or skip extra chemotherapy after surgery, based on whether the test finds any leftover cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with stage II (high-risk) or stage III (low-risk) colon cancer, and your tumor is not a type called MSI-H.
- Your tumor is located at least 12 cm from the anal opening (so it is not a rectal cancer).
- You have not had any chemotherapy or radiation for colon cancer before this trial.
- You are able to provide a tumor sample from surgery and blood samples to test for tiny amounts of cancer left behind (MRD testing).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different chemotherapy combinations given after surgery to prevent cancer from coming back in people with colorectal cancer who have minimal residual disease (MRD), meaning there are still tiny traces of cancer DNA in the blood. A more intense regimen may work better for this group, and the trial checks if it is safe and more effective.
This trial compares the effects of a combination of two chemotherapy drugs (CAPEOX) versus close monitoring (active surveillance) in early-stage colorectal cancer patients who have a positive MRD blood test after surgery. The goal is to see if giving chemotherapy can reduce the risk of cancer returning compared to just watching.
This trial looks at a personalized treatment approach for rectal cancer. It aims to guide the best chemotherapy and (if needed) radiotherapy before and after surgery, based on scans and specific test results.
This trial tests two chemotherapy drugs, capecitabine alone or with oxaliplatin, in people aged 70 or older after surgery for stage III colorectal cancer. The goal is to find out which treatment works better to prevent cancer from coming back.
This trial tests whether a special blood test that detects cancer DNA can help doctors decide if you need additional chemotherapy after colorectal cancer surgery. The goal is to personalize treatment based on your individual risk rather than giving chemotherapy to everyone.
This study tests whether giving additional (adjuvant) chemotherapy based on a special blood test—circulating tumor DNA (ctDNA)—can lower the risk of colon cancer coming back. It targets people with stage II–III colon cancer whose blood test is positive for minimal residual disease (MRD) after completing standard chemo.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.